Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | VDR | P11473 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557903 | 0.85 | GAA (0.52) | CA1CA2CA9CA12CA3 | |
| SCHEMBL2342945 | 0.85 | GAA (0.52) | CA1CA2CA9CA12CA3 | |
| SCHEMBL890642 | 0.83 | GAA (0.50) | CA1CA2CA9CA12CA3 | |
| SCHEMBL143705 | 0.83 | GAA (0.50) | CA1CA2CA9CA12CA3 | |
| SCHEMBL4671544 | 0.82 | GBA1 (0.42) | CA1CA2CA9CA12CA3 | |
| SCHEMBL2555662 | 0.82 | GAA (0.48) | CA1CA2CA9CA12CA3 | |
| SCHEMBL19949926 | 0.82 | GAA (0.48) | CA1CA2CA9CA12CA3 | |
| SCHEMBL6880747 | 0.82 | CA12 (0.43) | CA1CA2CA9CA12CA3 | |
| SCHEMBL1629581 | 0.82 | TLR9 (0.48) | CA1CA2CA9CA12CA3 | |
| SCHEMBL14778368 | 0.82 | TLR9 (0.48) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015345-A1 | ROUTE FOR CONSTRUCTING CHIRAL FRAGMENT OF FEZOLINETANT, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR | SHENZHEN HWAGEN PHARMACEUTICAL CO., LTD. (CN) | 2026-01-15 | — | — | US | claimed |
| CN-118878478-A | Route for constructing non-zolpidem chiral fragment, intermediate and preparation method thereof | 深圳市华先医药科技有限公司 | 2024-11-01 | — | — | CN | claimed |
| US-12559484-B2 | Route for constructing chiral fragment of fezolinetant, intermediate thereof, and preparation method therefor | SHENZHEN HWAGEN PHARMACEUTICAL CO., LTD. (CN) | 2026-02-24 | — | — | US | disclosed |
| US-20260015345-A1 | ROUTE FOR CONSTRUCTING CHIRAL FRAGMENT OF FEZOLINETANT, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR | SHENZHEN HWAGEN PHARMACEUTICAL CO., LTD. (CN) | 2026-01-15 | — | — | US | disclosed |
| CN-118878478-A | Route for constructing non-zolpidem chiral fragment, intermediate and preparation method thereof | 深圳市华先医药科技有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-109206417-B | Opioid receptor agonists and uses thereof | 四川海思科制药有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115124520-A | Opioid receptor agonists and uses thereof | 四川海思科制药有限公司 | 2022-09-30 | — | — | CN | disclosed |
| EP-3938045-A1 | SALTS OF A ISOCHROMANYL COMPOUND AND CRYSTALLINE FORMS, PROCESSES FOR PREPARING, THERAPEUTIC USES, AND PHARMACEUTICAL COMPOSITIONS THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020186165-A1 | SALTS OF A ISOCHROMANYL COMPOUND AND CRYSTALLINE FORMS, PROCESSES FOR PREPARING, THERAPEUTIC USES, AND PHARMACEUTICAL COMPOSITIONS THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| EP-0285671-B1 | PYRIDINE DERIVATIVES | ASAHI CHEMICAL IND (JP) | 2003-09-03 | — | — | EP | disclosed |
| EP-1261592-A1 | ISOTHIAZOLECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS MICROBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 2002-12-04 | — | — | EP | disclosed |
| US-5653970-A | CLEANING COMPOUNDS; COSMETICS | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1997-08-05 | — | — | US | disclosed |
| US-5641480-A | ENHANCED STABILITY AND/OR VISCOSITY, CLARITY | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1997-06-24 | — | — | US | disclosed |
| US-5624906-A | Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1997-04-29 | — | — | US | disclosed |
| US-5599587-A | Phosphoric acid esters and their use in the preparation of biocompatible surfaces | BIOCOMPATIBLES LIMITED (GB) | 1997-02-04 | — | — | US | disclosed |
| US-5521293-A | Heteroatom containing alkyl aldonamide compounds as superior foaming, more soluble nonionic surfactants and a process for their manufacture | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0556216-A1 | PHOSPHORIC ACID ESTERS AND THEIR USE IN THE PREPARATION OF BIOCOMPATIBLE SURFACES. | BIOCOMPATIBLES LTD (GB) | 1993-08-25 | — | — | EP | disclosed |
| US-5126448-A | Anxiolytic agents, learning enhancement | ASAHI KASEI KOGYO K.K. (JP) | 1992-06-30 | — | — | US | disclosed |
| WO-1992007858-A1 | PHOSPHORIC ACID ESTERS AND THEIR USE IN THE PREPARATION OF BIOCOMPATIBLE SURFACES | BIOCOMPATIBLES LIMITED (GB) | 1992-05-14 | — | — | WO | disclosed |
| EP-0285671-A1 | PYRIDINE DERIVATIVES | Asahi Kasei Kabushiki Kaisha (JP) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015345-A1 | ROUTE FOR CONSTRUCTING CHIRAL FRAGMENT OF FEZOLINETANT, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR | CYP19A1, CYP4F11, CYP11B1 | CA1 746/4885CA2 934/4885CA9 1586/4885 |
| US-12559484-B2 | Route for constructing chiral fragment of fezolinetant, intermediate thereof, and preparation method therefor | PTGIS, TMEM109, CYP11B1 | CA1 1250/4885CA2 1025/4885CA9 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.